3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
63
Neoplasms
5
Neoplasm Metastasis
5
Carcinoma, Intraductal, Noninfiltrating
3
Breast Neoplasms, Male
3
Recurrence
2
Ovarian Neoplasms
2
Endometrial Neoplasms
2
Breast Diseases
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Tuberous Sclerosis
1
Squamous Cell Carcinoma of Head and Neck
1
Sexual Dysfunctions, Psychological
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms by Site
1
Multiple Endocrine Neoplasia Type 1
1
Locoregional Recurrence
1
Hyperglycemia
1
Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
HER2-positive Breast Cancer
1
Granulosa cell tumor of the ovary
1
Endometrial Stromal Tumors
1
Endometrial Hyperplasia
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Interventions
pembrolizumab
14
Nivolumab
11
Ipilimumab
10
cabozantinib
6
Axitinib
6
belzutifan
5
Radiosurgery
5
atezolizumab
4
Sunitinib
4
palbociclib
3
lenvatinib
3
Surveys and Questionnaires
3
Radiotherapy
3
Pluvicto
3
Everolimus
3
Blood Specimen Collection
3
Biopsy
3
zimberelimab
2
pazopanib
2
cemiplimab
2
Therapeutics
2
Methods
2
Magnetic Resonance Spectroscopy
2
Irinotecan
2
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
2
trebananib
1
toripalimab
1
tocilizumab
1
temsirolimus
1
spartalizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Kidney Neoplasms
×
exemestane
×
1 year
×
Clear all
No trials found.